Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level

Authors:

Abstract
Two-step testing for Clostridioides difficile infection (CDI) aims to improve diagnostic specificity, but may also influence reported epidemiology and patterns of treatment. Some providers fear that two-step testing may result in adverse outcomes if C. difficile is under-diagnosed. Our primary objective was to assess the impact of two-step testing on reported incidence of hospital-onset CDI (HO-CDI). As secondary objectives, we assessed the impact of two-step testing on C. difficile-specific antibiotic use and colectomy rates as proxies for harm from underdiagnosis or delayed treatment. This longitudinal cohort study included 2,657,324 patient-days across eight regional hospitals from July 2017 through March 2022. Impact of two-step testing was assessed by time series analysis with generalized estimating equation regression models. Two-step testing was associated with a level decrease in HO-CDI incidence (incidence rate ratio 0.53, 95% CI 0.48-0.60, p<.0.001), a similar level decrease in utilization rates for oral vancomycin and fidaxomicin (utilization rate ratio 0.63, 95% CI 0.58-0.70, pC. difficile specific antibiotic use offers indirect reassurance against under-diagnosis of C. difficile infections still requiring treatment by clinician assessment. Similarly, the absence of any significant change in colectomy rates offers indirect reassurance against any rise in fulminant C. difficile requiring surgical management.
Funding Information
  • National Institutes of Health

This publication has 10 references indexed in Scilit: